ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,183.01
-0.09%
Dow Jones
39,022.81
-0.09%
US Dollar vs MXN
16.90949
-0.06%
Brent Oil
83.485
-0.09%
Bitcoin
60,992.61
-0.32%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. TC BioPharm Holdings PLC (TCBP)

  7. TC BioPharm Holdings PLC (TCBP) Noticias

TCBP TC BioPharm Holdings PLC

1.25
0.01 (0.81%)
Pre Mercado
Última actualización: 08:25:22
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
TC BioPharm Holdings PLC TCBP NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.01 0.81% 1.25 08:25:22
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.24
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
06/5/202412:01PRNUSTC BioPharm Announces Exercise of Warrants for £3.1 Million..
06/5/202407:30PRNUSTC BioPharm Announces Execution of Second Non-Binding Letter..
04/4/202407:32PRNUSTCBP Announces Execution of Non-Binding Letter of Intent for..
02/4/202407:30PRNUSTCBP Increasing Treatment Capacity with Expanded..
19/3/202407:30PRNUSTCBP Adjourns General Meeting Until a Later Date
18/3/202407:30PRNUSTCBP Announces Exercise of Series D Warrants For Cash
06/3/202405:30EDGAR2Form 8-K - Current report
01/3/202407:30PRNUSBryan Kobel, CEO of TCBP, Appears on Nationally Syndicated..
27/2/202416:15PRNUS/C O R R E C T I O N -- TC BioPharm/
27/2/202407:30PRNUSTCBP Announces Shareholder Update Call on March 5th 2024
22/2/202408:32PRNUSTCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK..
20/2/202405:05EDGAR2Form DEF 14A - Other definitive proxy statements
15/2/202407:30PRNUSTC BioPharm Management to Participate at Upcoming 7th..
14/2/202413:48EDGAR2Form 8-K - Current report
14/2/202407:30PRNUSTCBP Provides Shareholder Update and Highlights Upcoming..
09/2/202414:26EDGAR2Form PRE 14A - Other preliminary proxy statements
29/1/202408:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
29/1/202407:30PRNUSTC BioPharm Chief Executive Officer, Bryan Kobel Featured on..
18/1/202407:30PRNUSTC BioPharm to Present at the Sequire Investor Summit
04/1/202407:46EDGAR2Form 8-K - Current report
04/1/202407:30PRNUSTC BioPharm Regains Compliance with Nasdaq Minimum Bid Price..
03/1/202407:30PRNUSTC BioPharm Announces Additional Cost Reduction Steps to..
22/12/202307:30PRNUSTC BioPharm Announces Closing of $3.5 Million Public..
21/12/202316:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/12/202307:00PRNUSTC BioPharm Announces Pricing of $3.5 Million Public..
18/12/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
18/12/202310:15PRNUSTC BioPharm Announces Formation of Commercial Development..
14/12/202316:20EDGAR2Form F-1/A - Registration statement for certain foreign..
13/12/202308:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202305:30PRNUSTC BioPharm Announces Plan to Implement ADS Ratio Change
27/11/202307:45PRNUSTC BioPharm Announces FDA Clearance of Phase 1B IND for..
14/11/202309:00PRNUSTC BioPharm Announces Successful Completion of Safety Cohort..
08/11/202315:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
02/11/202312:30PRNUSTC BioPharm Announces Streamlined Efficiencies and Reduces..
02/11/202312:11EDGAR2Form F-3/A - Registration statement by foreign private..
02/11/202311:57EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/10/202307:00PRNUSTC BioPharm Selects Excellos as CDMO in Anticipation of..
23/10/202307:00PRNUSTC BioPharm Announces Submission of Investigational New Drug..
29/9/202315:05EDGAR2Form F-3 - Registration statement by foreign private issuers
27/9/202307:00PRNUSTC BioPharm to Present at the LD Micro Main Event XVI
05/9/202307:30PRNUSTC BioPharm Announces Grant Funding in Collaboration with..
01/9/202316:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
31/8/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202307:30PRNUSTC BioPharm to Present at H.C. Wainwright 25th Annual Global..
28/8/202316:25EDGAR2Form F-1 - Registration statement for certain foreign..
22/8/202315:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/7/202307:30PRNUSTC BioPharm Maintains Nasdaq Listing
31/7/202307:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202315:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/7/202316:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Su Consulta Reciente

NASDAQ
TCBP
TC BioPharm
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados